Oncology Intelligence — June 30, 2026
|
A non-covalent BTK inhibitor just cleared Europe’s CHMP for CLL across every line of therapy — Lilly’s Jaypirca (pirtobrutinib), backed by a head-to-head win over ibrutinib in treatment-naive patients, now has a credible path into the much larger frontline market.
Today’s top developments:
|
What to Watch
- Jaypirca’s EC decision and US filing — a European Commission ruling on the all-lines CLL recommendation is expected within one to two months, while the FDA decision is anticipated in the second half of 2026; together they set up Lilly’s non-covalent BTK inhibitor to contest the frontline CLL market held by covalent incumbents.
- Navtemadlin’s POIESIS readout — top-line Phase 3 data on the ruxolitinib add-on in TP53 wild-type myelofibrosis are expected in 2027, the event that determines whether Ipsen’s $1.25B in milestones beyond the $450M upfront ever gets paid and whether add-on combinations reshape the Jakafi-dominated market.
- CDx partnership dealmaking — the ASCO 2026 shift toward biomarker-gated Phase 3 designs is likely to accelerate companion-diagnostic deal activity in H2 2026 as mid-size oncology biotechs race to secure diagnostic integration before pivotal trial initiation.
- Pediatric transplant donor-selection data — the Children’s Oncology Group trial (NCT05457556) comparing mismatched related to matched unrelated donors could reshape pediatric transplant protocols within two to three years, with direct implications for access equity in ALL and AML patients lacking registry matches.
This brief highlights the edition’s top stories. Read the full June 30, 2026 edition → for all stories and analysis — or browse the Oncology archive.
